| Autor: |
Hodges RL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285., Hodges DW, Goggans K, Xuei X, Skatrud P, McGilvray D |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of industrial microbiology [J Ind Microbiol] 1994 Nov; Vol. 13 (6), pp. 372-81. |
| DOI: |
10.1007/BF01577222 |
| Abstrakt: |
The production of echinocandin B (ECB), a lipopolypeptide used for chemical manufacture of the anti-Candida agent Cilofungin, was accomplished by fermentation using a strain of Aspergillus nidulans. In addition to ECB, this fermentation also produces a significant amount of sterigmatocystin (ST), a potent carcinogen structurally related to the aflatoxins. Mutants blocked in the ST biosynthetic pathway were created by genetic modification of the polyploid production strain C747. The following steps were involved: (i) reduction of the genotype to haploid by treatment with the spindle fiber poison methyl 1-(butylcarbamoyl)-2-benzimidazole carbamate (MBC), using colony morphology, conidia size, and the ability to obtain 5-fluoro-orotic acid (5-FOA)-resistant mutants as criteria for ploidy; (ii) mutagenesis of a haploid isolate using UV irradiation; and (iii) screening of mutants for inability to produce ST by thin layer chromatography. Six mutants blocked in ST production were isolated. All six remained capable of producing ECB equivalent in quantity to the haploid strain C747-GR14. One of the mutants was shown to be the result of a chromosomal translocation. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
